Section 4: Clinical Pharmacy Services

4CPS-203

COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS

4CPS-202

OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES

4CPS-200

EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE

4CPS-198

THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY

4CPS-197

Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs

4CPS-195

Medication-related readmissions: documentation and communication to the next healthcare providers and patients

ACPS-189

ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA

4CPS-183

Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device

4CPS-176

ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY

4CPS-175

MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS

4CPS-164

DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS

4CPS-157

IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES

4CPS-155​

APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT

4CPS-150

Ability to assess acute kidney injury in patients admitted to hospital

4CPS-148

Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients

Pages